GlassScriptPhysician profile
Mohammad M Ahmed
NPI 1386636447
$4,893.33
in general payments reported to CMS, 2019-2025
39 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $214 · 2021: $527 · 2022: $831 · 2023: $907 · 2024: $935 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.98 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $470.37 | 2019-2025 | |
| Novo Nordisk INC | $455.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $385.11 | 2019-2025 | Breztri, Airsupra, Saphnelo |
| Lilly USA, LLC | $307.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $248.81 | 2023-2025 | Freestyle Libre 3, Amplatzer Amulet, Proclaim |
| Edwards Lifesciences Corporation | $152.68 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sumitomo Pharma America, INC. | $139.27 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $133.07 | 2022-2024 | Injectafer |
| Esperion Therapeutics, INC. | $122.00 | 2024-2025 | Nexletol, Nexlizet |
| Janssen Biotech, INC. | $119.79 | 2020-2025 | Tremfya |
| Biohaven Pharmaceutical Holding Company LTD. | $116.71 | 2022 | |
| Glaxosmithkline, LLC. | $116.57 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $102.31 | 2020-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $99.57 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.